RNA241220C33000
- 5.80
- 0.000.00%
Avidity Biosciences Newsroom
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
Avidity Biosciences to Participate in Upcoming Investor Conference
RBC Initiates Avidity Biosciences at Outperform, Speculative Risk With $67 Price Target
RBC Capital Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $67
Express News | Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Insider Sale: Chief Human Resources Officer of $RNA (RNA) Sells 25,000 Shares
RNA Stock Hits Record High on Entering the Cardiac Disease Space
Avidity Biosciences: Expanding Horizons in Precision Cardiology With New Genetic Targets
Avidity Biosciences Price Target Maintained With a $65.00/Share by Chardan Capital
Avidity Biosciences Is Maintained at Buy by Chardan Capital
Avidity Biosciences Jumps 16%; Reaches All-time High
Express News | Avidity Biosciences Shares Are Trading Higher. Needham Reiterated a Buy Rating on the Stock
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $78
TD Cowen Reaffirms Their Buy Rating on Avidity Biosciences (RNA)
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $51 to $65
Avidity Biosciences (RNA) Gets a Buy From Barclays
Avidity Biosciences Analyst Ratings
Promising Outlook for Avidity Biosciences: Strategic Focus on Genetic Targeting and Innovative AOC Technology
Buy Rating Affirmed for Avidity Biosciences Amid Precision Cardiology Advancements